Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iTeos: Developing IO Therapeutics For Hot And Cold Tumors

Executive Summary

Emerging Company Profile: Not many young academic spin-outs can claim a clinical-stage collaboration with a big pharma, but iTeos Therapeutics ‒ a Belgian company developing novel cancer therapies ‒ can do just that.

You may also be interested in...



A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug

Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.

An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics

Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.

Scrip's Rough Guide To IDO

IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel